Skip to main content

Table 4 Least squares (LS) means scoresa (95% Confidence intervals, CIs) of HRQoL according to quartiles of Western dietary pattern in breast cancer survivors

From: Dietary pattern and health-related quality of life among breast cancer survivors

  

Quartiles of Western dietary pattern

 

Variables

N (=232)

Quartile 1

Quartile 2

Quartile 3

Quartile 4

P for trend

EORTC QLQ - C30

 Global health status/QoL

200

33.35 (23.82 - 46.70)

36.10 (25.92 - 50.27)

34.29 (24.56 - 47.89)

43.52 (31.43 - 60.25)

0.22

Functioning

 Physical Functioning

228

67.65 (60.64 - 75.46)

77.67 (69.77 - 86.45)

81.89 (73.67 - 91.03)

77.41 (69.47 - 86.24)

0.06

 Role Functioning

229

57.02 (45.20 - 71.93)

70.04 (55.73 - 88.02)

79.94 (63.68 - 100.34)

70.20 (55.45 - 88.88)

0.15

 Emotional Functioning

230

63.32 (52.75 – 76.00)

70.77 (59.14 - 84.69)

77.86 (65.12 - 93.10)

66.73 (55.55 - 80.15)

0.61

 Cognitive Functioning

230

74.49 (65.26 - 85.03)

70.71 (62.09 - 80.53)

78.88 (69.30 - 89.78)

73.62 (64.47 - 84.06)

0.86

 Social Functioning

230

62.80 (50.07 - 78.78)

61.88 (49.52 - 77.32)

66.70 (53.43 - 83.26)

53.96 (42.98 - 67.73)

0.34

Symptom

 Fatigue

229

25.62 (18.52 - 35.43)

20.78 (15.17 - 28.46)

22.48 (16.42 - 30.77)

23.91 (17.34 - 32.96)

0.88

 Nausea and vomiting

230

4.96 (3.15 - 7.82)

2.53 (1.62 - 3.95)

2.17 (1.39 - 3.39)

3.84 (2.43 - 6.06)

0.46

 Pain

229

12.87 (7.72 - 21.45)

8.12 (4.94 - 13.33)

8.19 (4.99 - 13.44)

8.22 (4.95 - 13.63)

0.21

 Dyspnea

228

4.23 (2.45 - 7.30)

6.61 (3.89 - 11.22)

3.76 (2.21 - 6.39)

4.50 (2.62 - 7.73)

0.78

 Insomnia

228

24.84 (14.51 - 42.52)

11.00 (6.52 - 18.55)

16.76 (9.96 - 28.19)

18.81 (11.04 - 32.05)

0.75

 Loss of appetite

228

3.33 (1.98 - 5.61)

3.08 (1.85 - 5.11)

2.64 (1.59 - 4.37)

3.65 (2.18 - 6.13)

0.83

 Constipation

228

4.44 (2.56 - 7.70)

4.46 (2.61 - 7.60)

4.67 (2.74 - 7.96)

8.09 (4.69 - 13.94)

0.07

 Diarrhea

230

2.46 (1.50 - 4.04)

1.9 (1.17 - 3.10)

3.28 (2.02 - 5.33)

2.47 (1.50 - 4.06)

0.67

 Financial impact

230

9.92 (5.65 - 17.43)

6.97 (4.01 - 12.14)

6.45 (3.72 - 11.20)

6.42 (3.65 - 11.3)

0.24

EORTC QLQ-BR23

Functioning

 Body image

229

38.50 (26.43 - 56.06)

30.60 (21.23 - 44.12)

41.82 (29.06 - 60.19)

31.51 (21.69 - 45.77)

0.62

 Sexual functioning

216

4.15 (2.46 – 7.00)

2.23 (1.32 - 3.76)

4.77 (2.81 - 8.08)

4.08 (2.40 - 6.93)

0.55

 Future perspective

229

18.36 (10.99 - 30.67)

22.97 (13.94 - 37.85)

28.15 (17.13 - 46.27)

15.63 (9.39 - 26.03)

0.64

Symptom

 Systematic therapy side effects

230

24.90 (18.63 - 33.29)

19.03 (14.31 - 25.32)

18.20 (13.69 - 24.18)

22.45 (16.78 - 30.04)

0.65

 Breast symptoms

230

16.03 (10.35 - 24.83)

7.07 (4.60 - 10.87)

8.36 (5.45 - 12.82)

10.97 (7.07 - 17.01)

0.35

 Arm symptoms

230

27.23 (18.22 - 40.71)

21.05 (14.18 - 31.25)

20.81 (14.04 - 30.85)

20.65 (13.8 - 30.91)

0.32

 Upset by hair loss

151

24.94 (12.52 - 49.66)

29.96 (14.49 - 61.98)

34.18 (16.69 – 70.00)

17.16 (8.42 - 34.97)

0.44

  1. LS means least squares means, 95% CI 95% confidence interval, HRQoL health-related quality of life, EORTC QLQ- C30 European Organization for Research and Treatment of Cancer Quality of Life Questionnaire Core 30, BR23 breast cancer module 23
  2. aAdjusted for age at diagnosis (year; continuous), body mass index at diagnosis (kg/m2; continuous), energy intake (kcal/d; continuous), marital status (married or cohabitation, others), education level (high school or below, college or above), physical activity (MET-hr/wk.; continuous), breast cancer stage at diagnosis (I,II,III), time since surgery (months; continuous) and menopausal status at diagnosis (premenopausal, postmenopausal status)